Network Analysis Identifies SOD2 mRNA as a Potential Biomarker for Parkinson's Disease |
| |
| Authors: | Jose A. Santiago Clemens R. Scherzer Judith A. Potashkin |
| |
| Affiliation: | 1. The Cellular and Molecular Pharmacology Department, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, United States of America.; 2. The Neurogenomics Laboratory, Harvard Medical School and Brigham and Women''s Hospital, Cambridge, Massachusetts, United States of America.; Semmelweis University, Hungary, |
| |
| Abstract: | Increasing evidence indicates that Parkinson''s disease (PD) and type 2 diabetes (T2DM) share dysregulated molecular networks. We identified 84 genes shared between PD and T2DM from curated disease-gene databases. Nitric oxide biosynthesis, lipid and carbohydrate metabolism, insulin secretion and inflammation were identified as common dysregulated pathways. A network prioritization approach was implemented to rank genes according to their distance to seed genes and their involvement in common biological pathways. Quantitative polymerase chain reaction assays revealed that a highly ranked gene, superoxide dismutase 2 (SOD2), is upregulated in PD patients compared to healthy controls in 192 whole blood samples from two independent clinical trials, the Harvard Biomarker Study (HBS) and the Diagnostic and Prognostic Biomarkers in Parkinson''s disease (PROBE). The results from this study reinforce the idea that shared molecular networks between PD and T2DM provides an additional source of biologically meaningful biomarkers. Evaluation of this biomarker in de novo PD patients and in a larger prospective longitudinal study is warranted. |
| |
| Keywords: | |
|
|
